drugset / Trial / NCT07025824

Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation

NCT07025824

Phase 2 Not yet recruiting 220 enrolled Technical University Dresden medac GmbH · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to compare the effectiveness and tolerability of two conditioning chemotherapies prior to allogeneic stem cell transplantation. The following will also be investigated: * Survival * Remission and Relapse rate * Engraftment or graft failure * Graft versus Host Disease (GvHD)

Timeline

Start
2025-09
Primary completion
2028-12
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Melphalan Small molecule 140 mg/m2 Intravenous
Subject Treosulfan Small molecule 2 mg/m2 Intravenous
Subject Treosulfan Small molecule 10 g Intravenous
Background Fludarabine Small molecule 30 mg/m2 Intravenous